一种新型益生菌对糖尿病前期及近期诊断的2型糖尿病成人代谢生物标志物的影响:随机对照试验研究方案
本研究为双盲、安慰剂对照的先导性试验方案,计划纳入60名体重指数≥25 kg/m²的糖尿病前期或12个月内诊断的2型糖尿病成人,随机接受多菌种益生菌或安慰剂12周,两组均接受生活方式与营养建议。主要结局为12周时组间空腹血糖变化,次要结局包括血脂谱、全身炎症、肠道通透性及粪便微生物与代谢组谱。
要点
- 研究纳入体重指数≥25 kg/m²的糖尿病前期或12个月内诊断的2型糖尿病成人60名。
- 受试者随机接受多菌种益生菌或安慰剂12周,两组均接受生活方式与营养建议。
- 主要结局为12周时组间空腹血糖变化,次要结局包括血脂谱、全身炎症、肠道通透性及粪便微生物与代谢组谱。
核心结论
- 有意调控胃肠道微生物谱可能有助于预防和控制2型糖尿病及其相关代谢并发症。
研究设计与样本
- 双盲、安慰剂对照的先导性研究,计划纳入60名体重指数≥25 kg/m²的糖尿病前期或12个月内诊断的2型糖尿病成人。
- 参与者随机接受多菌种益生菌或安慰剂12周,两组均接受生活方式与营养建议。
主要发现
- 主要结局指标为从基线至12周时组间空腹血糖水平的变化。
- 次要结局指标包括血脂谱、全身炎症、肠道通透性及粪便微生物与代谢组谱的变化,但不限于此。
- 基线和治疗12周后采集血液和粪便样本。
关键数值与推荐
- 纳入标准:体重指数≥25 kg/m²的糖尿病前期或2型糖尿病(诊断于之前12个月内)成人。
- 主要结局:从基线至12周时组间空腹血糖水平的变化。
- 次要结局包括血脂谱、全身炎症、肠道通透性及粪便微生物与代谢组谱的变化,但不限于此。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shifts in the gastrointestinal microbiome have been shown to contribute to the progression of metabolic diseases including prediabetes and type 2 diabetes mellitus. Research suggests that in-vivo modulation of the gut microbiome by specific probiotic microorganisms may improve insulin sensitivity and blood sugar management, preventing or delaying the development of type 2 diabetes mellitus. However, further research is needed to understand the effect of probiotics as a therapy for the treatment of metabolic diseases. An evidence-based multi-species probiotic was developed to encourage a shift in the gastrointestinal bacterial cohort from a disease-prone to a balanced state with the aim of improving metabolic markers associated with type 2 diabetes mellitus. METHODS: Sixty adults with a body mass index ≥25 kg/m2 with prediabetes or type 2 diabetes mellitus (diagnosed within the previous 12 months) will be enrolled in a double-blind, placebo-controlled pilot study. Participants will be randomized to a multi-species probiotic or placebo for 12 weeks. Both groups will receive lifestyle and nutritional advice. The primary outcome measure is the change between groups in fasting plasma glucose levels from baseline to 12 weeks. Secondary outcome measures include, but are not limited to, the change in lipid profile, systemic inflammation, gut permeability, and faecal microbial and metabolomic profiles. Blood and stool samples are collected at baseline and 12 weeks after treatment. DISCUSSION: Intentional manipulation of gastrointestinal microbial profiles may be useful for preventing and controlling type 2 diabetes mellitus and its associated metabolic complications. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12613001378718 . Registered on 16 December 2013.
引用
- Palacios T, Vitetta L, Coulson S, et al. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28069054. doi:10.1186/s13063-016-1762-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。